Clinical trial
A Multicenter, Randomized, Double-Blind, Placebo-Controlled Phase 2 Study of Avatrombopag for Persistent Chemotherapy-Induced Thrombocytopenia in Patients With Gastrointestinal Malignancies (ACT-GI)
NCT05772546 is registered in ClinicalTrials.gov with Hanny Al-Samkari, MD as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Multicenter, Randomized, Double-Blind, Placebo-Controlled Phase 2 Study of Avatrombopag for Persistent Chemotherapy-Induced Thrombocytopenia in Patients With Gastrointestinal Malignancies (ACT-GI)
- Lead sponsor
- Hanny Al-Samkari, MD
- Phase
- Phase 2
- Overall status
- Completed
- Start date
- November 1, 2023
- Completion date
- April 20, 2026
- Enrollment
- 49 (actual)
- Sites
- 4
Conditions
As the registry lists them; a condition with its own page is linked.
chemotherapy-induced thrombocytopenia, gastrointestinal cancer, gastrointestinal neoplasms